Kailera director reports stock option holdings
Kailera Therapeutics director Martin Mackay filed an initial ownership report showing a stock option position rather than a new share purchase or sale.
Rhea-AI Filing Summary
Kailera Therapeutics director Martin Mackay filed an initial ownership report showing a stock option position rather than a new share purchase or sale. The option covers 170,194 shares of Common Stock with an exercise price of $11.56 per share and expires on March 10, 2036.
According to the vesting terms, 25% of the total shares vest on March 10, 2027, with the remaining options vesting in 36 substantially equal monthly installments, contingent on his continued service with the company.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
MACKAY MARTIN
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Stock Option (right to buy) | -- | -- | -- |
Holdings After Transaction:
Stock Option (right to buy) — 170,194 contracts (Direct)
Footnotes (1)
- F1. The options vest and become exercisable as to 25% of the total shares on March 10, 2027 and thereafter in 36 substantially equal monthly installments, subject to the Reporting Person's continued service on each such vesting date.
Key Figures
Underlying option shares: 170,194 shares
Exercise price: $11.56 per share
Option expiration: March 10, 2036
+2 more
5 metrics
Underlying option shares
170,194 shares
Common Stock underlying reported stock option holding
Exercise price
$11.56 per share
Strike price of Stock Option (right to buy)
Option expiration
March 10, 2036
Expiration date of the stock option award
Initial vesting milestone
25% on March 10, 2027
First vesting tranche of the stock option
Subsequent vesting period
36 monthly installments
Remaining vesting schedule after March 10, 2027
Key Terms
Stock Option (right to buy), underlying security, exercise price, expiration date, +1 more
5 terms
Stock Option (right to buy) financial
"security_title: "Stock Option (right to buy)""
underlying security financial
"underlying_security_title: "Common Stock""
exercise price financial
"conversion_or_exercise_price: "11.5600""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date: "2036-03-10T00:00:00.000Z""
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
vesting financial
"The options vest and become exercisable as to 25% of the total shares"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does Martin Mackay’s Form 3 filing for Kailera Therapeutics (KLRA) report?
The Form 3 reports Martin Mackay’s initial ownership of a stock option on Kailera Therapeutics shares. It discloses a right to buy 170,194 shares of Common Stock, providing a baseline view of his equity-linked position as a director.
What is the exercise price and expiration date of Martin Mackay’s KLRA stock option?
The stock option has an exercise price of $11.56 per share and an expiration date of March 10, 2036. These terms define the cost to acquire each share and the final date by which the option must be exercised before it lapses.
How does the vesting schedule work for Martin Mackay’s Kailera Therapeutics option?
The option vests 25% of the total shares on March 10, 2027, then in 36 substantially equal monthly installments. Vesting is conditioned on his continued service, so each future vesting date requires him to remain with the company for additional portions to become exercisable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
